NL-OMON28312已完成不适用
The (cost-)effectiveness of neoadjuvant FOLFIRINOX versus neoadjuvant Gemcitabine based chemoradiotherapy and adjuvant Gemcitabine for (borderline) resectable pancreatic cancer - PREOPANC-2 study
Erasmus MC University Medical Center, Department of Surgery0 个研究点目标入组 368 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 368
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Histologically or cytologically confirmed pancreatic cancer (i.e. pancreatic ductal adenocarcinoma)
- •(Borderline) resectable tumor without metastatic disease* (DPCG definitions of resectability)
排除标准
- •Prior radiotherapy, chemotherapy, or resection for pancreatic cancer.
- •Prior radiotherapy or chemotherapy precluding chemoradiotherapy or FOLFIRINOX.
研究者
相似试验
招募中
3 期
The (cost)effectiveness of neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine based chemoradiotherapy and adjuvant gemcitabine for (borderline) resectable pancreatic cancer.(borderline) resectable pancreatic cancer1001567410017991pancreatic cancerNL-OMON55463Erasmus MC, Universitair Medisch Centrum Rotterdam368
招募中
3 期
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)2024-516260-29-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)368
招募中
不适用
A trial of Neoadjuvant modified FOLFIRINOX chemotherapy for resectable pancreatic adenocarcinomaNeoplasmsKCT0004421Yonsei University Health System, Severance Hospital27
已完成
2 期
The feasibility and efficacy of neoadjuvant FOLFOXIRI followed by laparoscopic surgery for locally advaned rectal cancer: A phase II studycolorectal cancerJPRN-UMIN000026575Osaka Medical College Hospital58
尚未招募
Unknown
Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer: an international multicenter randomized controlled trialKCT0008360Seoul National University Hospital609